OPRK1 (Kappa Opioid Receptor) Drug Discovery Landscape & Assay Solutions
- By admin
- 24 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Pain, Pruritus, and Psychiatric Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OPRK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | OPRK1 Lentivirus Particles (Full-length human OPRK1 NM_000912, C-terminal Flag tag, titer >1×10⁸ TU/ml, endotoxin <1 EU/ml). Enables rapid HEK293/CHO stable cell line generation. Sequence verified. | View OPRK1 Products |
| Stable Cell Line | OPRK1-HEK293 Pre-constructed polyclonal stable line. High surface expression validated by anti-Flag flow cytometry. Ready for cAMP, calcium flux, and internalization assays. | View OPRK1 Products |
| Ortholog Panel | Cynomolgus / Mouse / Rat OPRK1 Lentivirus. Species-matched ORFs for seamless preclinical translation. Sequence verified against reference genomes (>95% identity). | View OPRK1 Products |
| Benchmark Ab / Peptide | Anti-OPRK1 control ligands (recombinant positive control for binding assays). For assay validation and specificity. | View OPRK1 Products |
| Validator (siRNA) | OPRK1 siRNA set (3 HPLC-purified duplexes targeting distinct CDS regions). For knockdown verification and background specificity checks. | View OPRK1 Products |
| Related Target | OPRM1 (Mu Opioid Receptor). Critical safety counter-screen for respiratory depression and addiction liability. | View OPRM1 Products |
| Related Target | OPRD1 (Delta Opioid Receptor). Family selectivity profiling for off-target liability assessment. | View OPRD1 Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Membrane Conformation & Glycosylation | Lentiviral delivery preserves native membrane insertion and mammalian glycosylation (HEK293). Essential for complex GPCR pharmacology. |
| Subfamily Counter Screening (OPRM1/OPRD1) | Matching stable cell lines for all three opioid receptors. Parallel screening for exact family selectivity determination. |
| Cross-species Translational Evaluation | Ortholog lentivirus panel (cyno, mouse, rat) enables seamless in vitro-to-in vivo transition. |
| Biased Signaling Detection (G-protein vs β-arrestin) | Functional cell lines compatible with GloSensor cAMP (Gαi) and PathHunter β-arrestin recruitment assays. |
| Assay Controls (Background & Specificity) | Validated siRNAs, benchmark ligands, and empty vector controls included to eliminate false positives. |
| Internalization & Trafficking Studies | High surface expression (>95% transduction efficiency) supports robust imaging and flow cytometry-based endocytosis assays. |
Live OPRK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Biased Signaling & Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The OPRK1 (KOR) therapeutic landscape is pivoting from first-generation CNS-penetrant agonists (associated with dysphoria and psychotomimetic effects) toward peripherally-restricted and G-protein-biased modalities. Following the FDA approval of difelikefalin (Cara Therapeutics) for CKD-associated pruritus, the industry is reinvesting across multiple indications. Major players including Eli Lilly and AbbVie (via Cerevel) are prioritizing KOR antagonists for treatment-resistant depression and substance use disorders, while novel analgesics focus on visceral and neuropathic pain without CNS liabilities. The next wave emphasizes pathway-selective ligands (biased agonism) that uncouple analgesic efficacy from aversive side effects through arrestin-independent signaling, and broadens therapeutic reach into psychiatric diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peripheral KOR Agonist (Peptide) | Cara Therapeutics, Maruishi | Pruritus (CKD, atopic), Visceral Pain | Selectivity screening vs OPRM1/OPRD1 using parallel stable cell lines |
| Small Molecule Biased Agonist (G-protein) | Centessa, AbbVie | Pain, Neuropathy | Biased signaling assays: cAMP inhibition vs β-arrestin recruitment |
| KOR Antagonist | Eli Lilly, AbbVie/Cerevel | Major Depression, Substance Use Disorder | Functional inverse agonist assays; high-expression cell lines for receptor occupancy |
| Monoclonal Antibody | Various (Preclinical) | Inflammatory Pain | High-density surface expression requiring efficient lentiviral delivery |
| Peptide Derivatives (Emerging) | Academic / Emerging Biotech | Peripheral Analgesia | Endocytosis and trafficking assays using lentivirus-expressed receptor |